Spotlight on anti-CD25: daclizumab in MS.

Abstract

Monoclonal antibodies are a promising new class of therapeutic agents that can be employed to target specific molecules of the immune system or any tissue. They are currently being tested in a number of clinical trials in autoimmune diseases such as multiple sclerosis (MS). One of these, the humanized monoclonal anti-CD25 antibody daclizumab (Zenapax), is directed against the interleukin-2 (IL-2) receptor alpha chain (CD25) that is involved in clonal expansion of autoreactive T-cells by binding of its ligand IL- 2. Several years ago daclizumab was approved for the prevention of renal allograft rejection. Following promising observations in uveitis, daclizumab has since been tested in a number of small clinical trials in MS based on the rationale that blocking CD25 would prevent the expansion of autoreactive T-lymphocytes. Safety and efficacy data from the preliminary clinical exploration as well as findings about the mechanism of action of anti-CD25 treatment are reviewed here.

• Authors: Dr Sven Schippling, Roland Martin
• Journal: International MS journal (Int MS J) Vol. 15 Issue 3 Pg. 94-8 (Sep 2008) ISSN: 1352-8963 [Print] England
• PMID: 18808743 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Immunoglobulin G
• Immunosuppressive Agents
• Interleukin-2 Receptor alpha Subunit
• Daclizumab

Topics

• Antibodies, Monoclonal (adverse effects, therapeutic use)
• Antibodies, Monoclonal, Humanized
• Clinical Trials as Topic
• Daclizumab
• Humans
• Immunoglobulin G (adverse effects, therapeutic use)
• Immunosuppressive Agents (adverse effects, therapeutic use)
• Interleukin-2 Receptor alpha Subunit (antagonists & inhibitors)
• Multiple Sclerosis, Chronic Progressive (drug therapy)
• Multiple Sclerosis, Relapsing-Remitting (drug therapy)